source
- AstraZeneca acquires Omniose to boost conjugate vaccine platform as FDA flags vision-loss risk for GLP-1 drugsAstraZeneca announced it has acquired vaccine startup Omniose, though the financial terms were not disclosed. The purchase gives AstraZeneca access to Omniose's bioconjugation technology, a method…
- Dual targeting of GPCRs and mutated Gαq/11 shows promise for uveal melanomaResearchers at Thomas Jefferson University reported a new strategy to disrupt signaling in uveal melanoma, a rare eye cancer. The study found that simultaneously inhibiting the G protein-coupled r…